The Alzheimer's disease market reached a value of US$ 3.1 Billion across the top 7 markets (US, EU4, UK, and Japan) in 2023. Looking forward, the publisher expects the top 7 markets to reach US$ 6.3 Billion by 2034, exhibiting a growth rate (CAGR) of 8.20% during 2023-2034.
The Alzheimer's disease market has been comprehensively analyzed in this report titled "Alzheimer's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alzheimer's disease (AD) refers to a neurodegenerative disorder characterized by the degeneration of nerve cells in several areas of the brain that control thought, memory, and language. The most common symptoms include memory impairment, depression, loss of inhibitions, etc. As the disease progresses, symptoms may include issues with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral problems. Alzheimer's disease currently represents the seventh leading cause of death among all diseases and one of the biggest causes of disability and dependency among the geriatric population. Alzheimer's disease has physical, psychological, social, and economic impacts, not only for individuals living with the disease, but also for their carers, families, and society at large.
The Alzheimer's disease market is primarily driven by a rising geriatric population, who are more prone to neurodegenerative disorders. In over 90% of patients with Alzheimer's, symptoms do not appear till the age 60. Furthermore, incidence of the disease rises with age and doubles every 5 years after age 65. In addition to the rising ageing population, Alzheimer's disease market is also driven by improving diagnosis and drug treatment rates which includes a rising adoption of newer diagnostic techniques for early diagnosis. Furthermore, the ongoing development of several novel therapeutics that have a strong safety and efficacy profile is also expected to catalyze the growth of the market in the coming years.
This report provides an exhaustive analysis of the Alzheimer's disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Alzheimer's disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Alzheimer's disease market in any manner.
Recent Developments:
In April 2024, Eisai Co., Ltd. and Biogen Inc. jointly announced that Eisai had filed a supplemental biologics license application to the U.S. FDA for monthly intravenous (IV) maintenance dosing of lecanemab-irmb (U.S. brand name: LEQEMBI). LEQEMBI is indicated to treat Alzheimer's disease in people with mild dementia or cognitive impairment.
In March 2024, TauRx Pharmaceuticals Ltd. released results from a prespecified examination of the phase 3 LUCIDITY trial, which measured the impact of hydromethylthionine mesylate (HMTM) on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration. The results revealed that HMTM combines two independent modes of action: inhibition of tau aggregation pathology in the brain and a second symptomatic activity.
In February 2024, GSK and Alector announced the initiation of the global PROGRESS-AD Phase II clinical trial of AL101 in people with early Alzheimer's disease, including mild cognitive impairment and mild dementia due to AD.
In February 2024, a study by Matthew Adesuyan et al. suggested that the use of phosphodiesterase type 5 inhibitors may be associated with a reduced risk of incident AD in men. Researchers are reporting that erectile dysfunction drugs increase blood flow, which could help lower the risk of Alzheimer's.
In July 2023, Eli Lilly and Company disclosed findings from the TRAILBLAZER-ALZ 2 study, a phase 3 clinical trial analyzing the efficacy and safety of the N3pG antibody (donanemab) in participants with early symptomatic AD. The study revealed that donanemab effectively decelerated cognitive and functional decline in individuals exhibiting early signs of the disease.
Key Highlights:
Alzheimer's disease is the most common form of dementia, causing up to 70% of the 55 million dementia cases worldwide.
About 1% of cases of Alzheimer's disease are entirely caused by genes, and other genes increase the risk of developing Alzheimer's.
An estimated 6.9 million Americans aged 65 and older are living with Alzheimer's dementia in 2024.
Estimates suggest that 50% or more of people living with Down syndrome will develop Alzheimer's with symptoms appearing in their 50s and 60s.
A meta-analysis examining the incidence of Alzheimer's disease in Europe found that approximately 13 women out of 1,000 developed Alzheimer's each year, compared to only seven men.
Drugs:
Memantine (Namenda) is an FDA-approved drug for managing symptoms associated with moderate to severe stages of Alzheimer's disease. Its mechanism involves diminishing the levels of the neurotransmitter glutamate in the brain. This therapeutic agent can be administered independently or in conjunction with a cholinesterase inhibitor.
COYA-301 is under development by Coya Therapeutics for the treatment of AD. It is administered through a subcutaneous route. The therapeutic candidate is a combination immunotherapy designed to lower activated T effector cells and activated macrophages/microglia while increasing peripheral T cell regulatory (Treg) function and numbers.
The Alzheimer's disease market has been comprehensively analyzed in this report titled "Alzheimer's Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Alzheimer's disease (AD) refers to a neurodegenerative disorder characterized by the degeneration of nerve cells in several areas of the brain that control thought, memory, and language. The most common symptoms include memory impairment, depression, loss of inhibitions, etc. As the disease progresses, symptoms may include issues with language, disorientation, mood swings, loss of motivation, self-neglect, and behavioral problems. Alzheimer's disease currently represents the seventh leading cause of death among all diseases and one of the biggest causes of disability and dependency among the geriatric population. Alzheimer's disease has physical, psychological, social, and economic impacts, not only for individuals living with the disease, but also for their carers, families, and society at large.
The Alzheimer's disease market is primarily driven by a rising geriatric population, who are more prone to neurodegenerative disorders. In over 90% of patients with Alzheimer's, symptoms do not appear till the age 60. Furthermore, incidence of the disease rises with age and doubles every 5 years after age 65. In addition to the rising ageing population, Alzheimer's disease market is also driven by improving diagnosis and drug treatment rates which includes a rising adoption of newer diagnostic techniques for early diagnosis. Furthermore, the ongoing development of several novel therapeutics that have a strong safety and efficacy profile is also expected to catalyze the growth of the market in the coming years.
This report provides an exhaustive analysis of the Alzheimer's disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for Alzheimer's disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Alzheimer's disease market in any manner.
Recent Developments:
In April 2024, Eisai Co., Ltd. and Biogen Inc. jointly announced that Eisai had filed a supplemental biologics license application to the U.S. FDA for monthly intravenous (IV) maintenance dosing of lecanemab-irmb (U.S. brand name: LEQEMBI). LEQEMBI is indicated to treat Alzheimer's disease in people with mild dementia or cognitive impairment.
In March 2024, TauRx Pharmaceuticals Ltd. released results from a prespecified examination of the phase 3 LUCIDITY trial, which measured the impact of hydromethylthionine mesylate (HMTM) on neurofilament light chain (NfL), an established biomarker for brain neurodegeneration. The results revealed that HMTM combines two independent modes of action: inhibition of tau aggregation pathology in the brain and a second symptomatic activity.
In February 2024, GSK and Alector announced the initiation of the global PROGRESS-AD Phase II clinical trial of AL101 in people with early Alzheimer's disease, including mild cognitive impairment and mild dementia due to AD.
In February 2024, a study by Matthew Adesuyan et al. suggested that the use of phosphodiesterase type 5 inhibitors may be associated with a reduced risk of incident AD in men. Researchers are reporting that erectile dysfunction drugs increase blood flow, which could help lower the risk of Alzheimer's.
In July 2023, Eli Lilly and Company disclosed findings from the TRAILBLAZER-ALZ 2 study, a phase 3 clinical trial analyzing the efficacy and safety of the N3pG antibody (donanemab) in participants with early symptomatic AD. The study revealed that donanemab effectively decelerated cognitive and functional decline in individuals exhibiting early signs of the disease.
Key Highlights:
Alzheimer's disease is the most common form of dementia, causing up to 70% of the 55 million dementia cases worldwide.
About 1% of cases of Alzheimer's disease are entirely caused by genes, and other genes increase the risk of developing Alzheimer's.
An estimated 6.9 million Americans aged 65 and older are living with Alzheimer's dementia in 2024.
Estimates suggest that 50% or more of people living with Down syndrome will develop Alzheimer's with symptoms appearing in their 50s and 60s.
A meta-analysis examining the incidence of Alzheimer's disease in Europe found that approximately 13 women out of 1,000 developed Alzheimer's each year, compared to only seven men.
Drugs:
Memantine (Namenda) is an FDA-approved drug for managing symptoms associated with moderate to severe stages of Alzheimer's disease. Its mechanism involves diminishing the levels of the neurotransmitter glutamate in the brain. This therapeutic agent can be administered independently or in conjunction with a cholinesterase inhibitor.
COYA-301 is under development by Coya Therapeutics for the treatment of AD. It is administered through a subcutaneous route. The therapeutic candidate is a combination immunotherapy designed to lower activated T effector cells and activated macrophages/microglia while increasing peripheral T cell regulatory (Treg) function and numbers.
Time Period of the Study
- Base Year: 2023
- Historical Period: 2018-2023
- Market Forecast: 2024-2034
Countries Covered
- United States
- Germany
- France
- United Kingdom
- Italy
- Spain
- Japan
Analysis Covered Across Each Country
- Historical, Current and Future Epidemiology Scenario
- Historical, Current and Future Performance of the Alzheimer's Disease Market
- Historical, Current and Future Performance of Various Therapeutic Categories in the Alzheimer's Disease Market
- Sales of Various Drugs Across the Alzheimer's Disease Market
Competitive Landscape:
This report also provides a detailed analysis of the current Alzheimer's Disease marketed drugs and late-stage pipeline drugs.In-Market Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
- Drug Overview
- Mechanism of Action
- Regulatory Status
- Clinical Trial Results
- Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
- How has the Alzheimer's Disease market performed so far and how will it perform in the coming years?
- What are the markets shares of various therapeutic segments in 2023 and how is it expected to be in 2034?
- What was the country-wise size of the Alzheimer's Disease market across the seven major markets in 2023 and how will it look like in 2034?
- What is the growth rate of the Alzheimer's Disease market across the seven major markets and what will be the expected growth over the next ten years?
- What are the key unmet needs in the Alzheimer's Disease market?
Epidemiology Insights
- What is the size of the Alzheimer's Disease patient pool (2018-2023) across the seven major markets?
- What would be the forecasted patient pool (2024-2034) of Alzheimer's Disease across the seven major markets?
- What are the key factors driving the epidemiological trend of Alzheimer's Disease?
- What will be the growth rate of Alzheimer's Disease patients across the seven major markets?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies
- What are the current marketed Alzheimer's Disease drugs and what are their market performance?
- What are the key pipeline Alzheimer's Disease drugs and how are they expected to perform in the coming years?
- How safe are the current marketed Alzheimer's Disease drugs and what are their efficacies?
- How safe are the late-stage pipeline Alzheimer's Disease drugs and what are their efficacies?
- What are the current treatment guidelines for Alzheimer's Disease drugs across the seven major markets?
- Who are the key companies in the Alzheimer's Disease market and what are their market shares?
- What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Alzheimer's Disease market?
Table of Contents
1 Preface3 Executive Summary6 Patient Journey9 Alzheimer’s Disease - Unmet Needs10 Alzheimer’s Disease - Key Endpoints of Treatment13. Alzheimer’s Disease - Attribute Analysis of Key Marketed and Pipeline Drugs15 Alzheimer’s Disease - Recent Events and Inputs From Key Opinion Leaders17 Appendix
2 Scope and Methodology
4 Alzheimer’s Disease - Introduction
5 Alzheimer’s Disease - Disease Overview
7 Alzheimer’s Disease - Epidemiology and Patient Population
8 Alzheimer’s Disease - Treatment Algorithm, Guidelines, and Medical Practices
11 Alzheimer’s Disease - Marketed Products
12 Alzheimer’s Disease - Pipeline Drugs
14 Alzheimer’s Disease - Market Scenario
16 Alzheimer’s Disease Market - SWOT Analysis
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 140 |
| Published | May 2024 |
| Forecast Period | 2023 - 2034 |
| Estimated Market Value ( USD | $ 3.1 Billion |
| Forecasted Market Value ( USD | $ 6.3 Billion |
| Compound Annual Growth Rate | 6.7% |
| Regions Covered | Global |
